Brazilian Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions

Study acronym: PCI EVOlution
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Apr 30, 2030 → Oct 1, 2030
See other at-risk trials from Scitech Produtos Medicos SA

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Start date pushed from Oct 1, 2026 to Oct 30, 2026
    • Primary and study completion dates: Oct 1, 2030 to Oct 30, 2030
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 1 of 7 entries
    • Site details revised
  2. Start date: Apr 30, 2026 to Oct 1, 2026
    • Primary and study completion pushed from Apr 30, 2030 to Oct 1, 2030
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population. Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions will be treated with the Inspiron™ EVO drug-eluting stent.
Trial Details
NCT Number NCT07491107
Lead Sponsor Scitech Produtos Medicos SA
Conditions
(from sponsor)		 Coronary Artery Disease (CAD), Stenosis Coronary, Small Vessel Ischemic Disease, Multivessel Coronary Artery Disease, Calcific Coronary Arteriosclerosis, Complex Coronary Lesions
Related terms Coronary Artery Disease, Coronary Stenosis
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov